Flagyl
PreclinicalSmall molecule
Flagyl is one of 35 small molecule programs targeting Chronic Periodontitis. It is currently in Preclinical.
1
Indications
9
Total Trials
0
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
65 competitors in Chronic Periodontitis
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Minocin
TTriax
Approved
Glucophage
Boehringer IngelheimApproved
Singulair
OOrganon and Co
Approved
Crestor
AstraZenecaPhase 3
Alendronate Sodium
Mylan Pharmaceuticals IncApproved
Propolis
IIndonesia University
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Fosamax
OOrganon and Co
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
AIN2 trials
Helicobacter Pylori Eradication1 trial
Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication
Completed·—·N/A·NCT02596620·164 enrolled
Combination Therapy1 trial
First-line1 trial
Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment
Completed·—·N/A·NCT05152004·240 enrolled
3 more indications
Helicobacter Pylori1 trial
Comparison of Two Novel First-line Anti-Helicobacter Pylori Therapy
Completed·—·N/A·NCT03383003·240 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Flagyl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPar Pharmaceutical, Inc.